特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
962453

前立腺がんの世界市場 (がんの種類別、薬剤別、治療法別、地域別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的影響 (2020~2024年)

Global Prostate Cancer Market (by Cancer Type, Drug, Therapy & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 147 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
前立腺がんの世界市場 (がんの種類別、薬剤別、治療法別、地域別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的影響 (2020~2024年)
出版日: 2020年09月29日
発行: Koncept Analytics
ページ情報: 英文 147 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺がんの市場規模は、2020~2024年に4.62%のCAGRで成長し、2024年には144億1000万米ドルに達すると予想されています。高齢者人口の増加や医療費の膨張、肥満人口の急増、都市化の拡大、新薬の承認といった要因が市場成長を促進すると見られています。地域別に見ると、北米諸国が最大の市場であり、欧州諸国がそれに次いでいます。

当レポートでは、世界の前立腺がん市場について分析し、疾患の概要や主な診断・治療法、世界全体の市場規模 - 患者数、治療薬の売上高 - の動向見通し (がん種類別、薬剤別、治療法別)、地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルなどを調査しております。

目次

第1章 市場概要

  • イントロダクション
  • 前立腺がんの種類
  • ステージング (病期段階) とグレーディング (悪性度)
  • 前立腺がんの症状
  • 前立腺がんの診断方法
  • 治療法
  • 前立腺がんの危険因子

第2章 COVID-19の影響

  • 前立腺がん市場への影響
  • がんの有病率への影響
  • 重大な有害事象のリスク要因
  • COVID-19流行中における前立腺がん患者の管理

第3章 世界市場の分析

  • 世界の前立腺がんの市場規模 (金額ベース)
  • 世界の前立腺がんの市場規模、予測値 (金額ベース)
  • 世界の前立腺がん市場:がんの種類別
    • ホルモン難治性前立腺がん
    • ホルモン感受性前立腺がん
  • 世界の前立腺がん市場:薬剤別
    • エンザルタミド
    • 酢酸アビラテロン
    • リュープロレリン
  • 世界の前立腺がん市場:治療法別
    • 化学療法
    • 標的療法
    • 免疫療法
    • ホルモン療法
  • 世界の前立腺がん市場:地域別

第4章 地域別の市場分析

  • 北米
    • 北米の前立腺がんの市場規模 (金額ベース)
    • 北米の前立腺がんの市場規模、予測値 (金額ベース)
    • 北米市場
      • がんの種類別
      • 薬剤別
  • 欧州市場
  • アジア太平洋市場
    • 中国市場
  • 他の国々 (RoW) の市場

第5章 市場力学

  • 成長促進要因
    • 高齢者人口の増加
    • 医療費の増大
    • 肥満人口の急増
    • 急速な都市化
    • 新薬の承認
  • 主な傾向と動静
    • 製薬産業の成長
    • 前立腺がんの負担の増大
    • 腫瘍研究の進歩
    • 社会的関心の増大
  • 課題
    • 治療の重篤な副作用
    • 高額の治療費
    • 長期の治療期間

第6章 競合情勢

  • 世界市場
    • 市場収益額の比較:主要企業間
    • 株式時価総額の比較:主要企業間
    • 研究開発費の比較:主要企業間
  • 承認された前立腺がん治療薬
  • 治験中の前立腺がん治療薬

第7章 企業プロファイル

  • Johnson & Johnson
  • Bayer AG
  • Sanofi S.A.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Astellas Pharma, Inc.
図表

List of Figures

  • Types of Prostate Cancer
  • Symptoms of Prostate Cancer
  • Types of Tests for Diagnosis of Prostate Cancer
  • Methods of Treatment
  • Risk Factors for Prostate Cancer
  • Global Cancer Prevalence (2018-2023)
  • Management of Prostate Cancer Patients During the COVID-19
  • Global Prostate Cancer Market by Value (2015-2019)
  • Global Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Prostate Cancer Market by Cancer Type (2019)
  • Global Hormone Refractory Prostate Cancer Market by Value (2015-2019)
  • Global Hormone Refractory Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Hormone Sensitive Prostate Cancer Market by Value (2015-2019)
  • Global Hormone Sensitive Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Prostate Cancer Market by Drug (2019)
  • Global Enzalutamide Prostate Cancer Market by Value (2015-2019)
  • Global Enzalutamide Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Abiraterone Acetate Prostate Cancer Market by Value (2015-2019)
  • Global Abiraterone Acetate Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Leuprorelin Prostate Cancer Market by Value (2015-2019)
  • Global Leuprorelin Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Prostate Cancer Market by Therapy (2019)
  • Global Chemotherapy Prostate Cancer Market by Value (2015-2019)
  • Global Chemotherapy Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Targeted Therapy Prostate Cancer Market by Value (2015-2019)
  • Global Targeted Therapy Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Immunotherapy Prostate Cancer Market by Value (2015-2019)
  • Global Immunotherapy Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Hormonal Therapy Prostate Cancer Market by Value (2015-2019)
  • Global Hormonal Therapy Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Prostate Cancer Market Value by Region (2019)
  • North America Prostate Cancer Market by Value (2015-2019)
  • North America Prostate Cancer Market Forecast by Value (2020-2024)
  • The U.S. Prostate Cancer Market by Value (2015-2019)
  • The U.S. Prostate Cancer Market Forecast by Value (2020-2024)
  • The U.S. Prostate Cancer Market by Drug (2019)
  • The U.S. Enzalutamide Prostate Cancer Market by Value (2015-2019)
  • The U.S. Enzalutamide Prostate Cancer Market Forecast by Value (2020-2024)
  • The U.S. Abiraterone Acetate Prostate Cancer Market by Value (2015-2019)
  • The U.S. Abiraterone Acetate Prostate Cancer Market Forecast by Value (2019-2024)
  • The U.S. Leuprorelin Prostate Cancer Market by Value (2015-2019)
  • The U.S. Leuprorelin Prostate Cancer Market Forecast by Value (2020-2024)
  • Europe Prostate Cancer Market by Value (2015-2019)
  • Europe Prostate Cancer Market Forecast by Value (2020-2024)
  • Asia Pacific Prostate Cancer Market by Value (2015-2019)
  • Asia Pacific Prostate Cancer Market Forecast by Value (2020-2024)
  • China Prostate Cancer Market by Value (2015-2019)
  • China Prostate Cancer Market Forecast by Value (2020-2024)
  • China Prostate Cancer Market by Drug (2019)
  • China Abiraterone Acetate Prostate Cancer Market by Value (2015-2019)
  • China Abiraterone Acetate Prostate Cancer Market Forecast by Value (2020-2024)
  • China Bicalutamide Prostate Cancer Market by Value (2015-2019)
  • China Bicalutamide Prostate Cancer Market Forecast by Value (2020-2024)
  • China Docetaxel Prostate Cancer Market by Value (2015-2019)
  • China Docetaxel Prostate Cancer Market Forecast by Value (2020-2024)
  • RoW Prostate Cancer Market by Value (2015-2019)
  • RoW Prostate Cancer Market Forecast by Value (2020-2024)
  • Global Population Above 65 Years (2015-2019)
  • Global Healthcare Expenditure Per Capita (2015-2019)
  • Global Obese Population (2014-2019)
  • Global Urban Population (2014-2019)
  • CDER's Novel Drug Approvals (2010-2019)
  • Global Pharmaceutical Market Revenue (2001-2021)
  • Total Number of Prostate Cancer Patients in the U.S. Rate (2018-2026)
  • Johnson & Johnson Sales and Net Earnings (2015-2019)
  • Johnson & Johnson Sales by Segment (2019)
  • Johnson & Johnson Sales by Region (2019)
  • Bayer AG Sales and Net Income (2015-2019)
  • Bayer AG Sales by Segment (2019)
  • Bayer AG Sales by Region (2019)
  • Sanofi S.A. Net Sales and Net Income (2015-2019)
  • Sanofi S.A. Net Sales by Segment (2019)
  • Sanofi S.A. Net Sales by Region (2019)
  • AbbVie Inc. Net Revenue and Net Earnings (2015-2019)
  • AbbVie Inc. Net Revenue by Region (2019)
  • AstraZeneca PLC Total Revenue and Profit (2015-2019)
  • AstraZeneca PLC Total Revenue by Region (2019)
  • Astellas Pharma, Inc. Revenue and Profit (2015-2019)
  • Astellas Pharma, Inc. Revenue by Product & Service (2019)
  • Astellas Pharma, Inc. Revenue by Region (2019)

List of Tables

  • Prostate Cancer Stages
  • Risk Factors for Severe Adverse Events (2020)
  • Severe Side-Effects by Type of Treatment
  • Revenue Comparison of Key Players (2019)
  • Market Capitalization Comparison of Key Players (2020)
  • R&D Expenditure Comparison of Key Players (2019)
  • Approved Drugs for Prostate Cancer
  • Experimental Agents of Prostate Cancer
目次

The global prostate cancer market is anticipated to reach US$14.41 billion in 2024, witnessing growth at a CAGR of 4.62%, over the period 2020-2024. Factors such as increasing geriatric population, rising healthcare expenditure, surging obese population, expanding urbanization, new drug approvals are expected to drive the market. The growth of the market would be challenged by severe side effects of the therapy, high cost associated with treatment and prolonged treatment durations. A few notable trends may include expansion of pharmaceutical industry, growing burden of prostate cancer and advancements in oncology.

The global prostate cancer market can be categorized on the basis of cancer type, drug and therapy. Depending upon the cancer type, the global prostate cancer market can broadly be divided into hormone refractory prostate cancer, hormone sensitive prostate cancer and other prostate cancer. According to drugs, the global prostate cancer market can be split into Enzalutamide, Abiraterone Acetate, Leuprorelin and other drugs. Whereas, in terms of therapy, the global prostate cancer market can be bifurcated into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and other therapies.

The fastest growing regional market is North America due to rising prevalence of prostate cancer in the region, highly competitive and developed medical sector, high investment in research and development activities for the development of newer immunotherapies and targeted drug therapies to treat various cancers. Europe represents the second largest prostate cancer market and is already well-penetrated at developed market levels.

Scope of the report:

  • The report provides a comprehensive analysis of the global prostate cancer market segmented on the basis of cancer type, drug, therapy and region.
  • The major regional and country markets (North America, Europe, Asia Pacific and Rest of the World) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Bayer AG, Sanofi S.A., AbbVie Inc., AstraZeneca PLC and Astellas Pharma, Inc.,) are also presented in detail.

Key Target Audience:

  • Prostate Cancer Drug Manufacturers
  • Prostate Cancer Medical Service Providers
  • Pharmaceuticals and Biopharmaceutical Firms
  • End Users (Hospitals, Cancer Research Institutes and Ambulatory & Radiotherapy Centers)
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Introduction
  • 1.2 Types of Prostate Cancer
  • 1.3 Staging and Grading
  • 1.4 Symptoms of Prostate Cancer
  • 1.5 Diagnosis of Prostate Cancer
  • 1.6 Methods of Treatment
  • 1.7 Risk Factors for Prostate Cancer

2. Impact of COVID-19

  • 2.1 Impact on Prostate Cancer Market
  • 2.2 Impact on Cancer Prevalence
  • 2.3 Risk Factors for Severe Adverse Events
  • 2.4 Management of Prostate Cancer Patients During the COVID-19

3. Global Market Analysis

  • 3.1 Global Prostate Cancer Market by Value
  • 3.2 Global Prostate Cancer Market Forecast by Value
  • 3.3 Global Prostate Cancer Market by Cancer Type
    • 3.3.1 Global Hormone Refractory Prostate Cancer Market by Value
    • 3.3.2 Global Hormone Refractory Prostate Cancer Market Forecast by Value
    • 3.3.3 Global Hormone Sensitive Prostate Cancer Market by Value
    • 3.3.4 Global Hormone Sensitive Prostate Cancer Market Forecast by Value
  • 3.4 Global Prostate Cancer Market by Drug
    • 3.4.1 Global Enzalutamide Prostate Cancer Market by Value
    • 3.4.2 Global Enzalutamide Prostate Cancer Market Forecast by Value
    • 3.4.3 Global Abiraterone Acetate Prostate Cancer Market by Value
    • 3.4.4 Global Abiraterone Acetate Prostate Cancer Market Forecast by Value
    • 3.4.5 Global Leuprorelin Prostate Cancer Market by Value
    • 3.4.6 Global Leuprorelin Prostate Cancer Market Forecast by Value
  • 3.5 Global Prostate Cancer Market by Therapy
    • 3.5.1 Global Chemotherapy Prostate Cancer Market by Value
    • 3.5.2 Global Chemotherapy Prostate Cancer Market Forecast by Value
    • 3.5.3 Global Targeted Therapy Prostate Cancer Market by Value
    • 3.5.4 Global Targeted Therapy Prostate Cancer Market Forecast by Value
    • 3.5.5 Global Immunotherapy Prostate Cancer Market by Value
    • 3.5.6 Global Immunotherapy Prostate Cancer Market Forecast by Value
    • 3.5.7 Global Hormonal Therapy Prostate Cancer Market by Value
    • 3.5.8 Global Hormonal Therapy Prostate Cancer Market Forecast by Value
  • 3.6 Global Prostate Cancer Market by Region

4. Regional Market Analysis

  • 4.1 North America
    • 4.1.1 North America Prostate Cancer Market by Value
    • 4.1.2 North America Prostate Cancer Market Forecast by Value
    • 4.1.3 The U.S. Prostate Cancer Market by Value
    • 4.1.4 The U.S. Prostate Cancer Market Forecast by Value
    • 4.1.5 The U.S. Prostate Cancer Market by Drug
    • 4.1.6 The U.S. Enzalutamide Prostate Cancer Market by Value
    • 4.1.7 The U.S. Enzalutamide Prostate Cancer Market Forecast by Value
    • 4.1.8 The U.S. Abiraterone Acetate Prostate Cancer Market by Value
    • 4.1.9 The U.S. Abiraterone Acetate Prostate Cancer Market Forecast by Value
    • 4.1.10 The U.S. Leuprorelin Prostate Cancer Market by Value
    • 4.1.11 The U.S. Leuprorelin Prostate Cancer Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe Prostate Cancer Market by Value
    • 4.2.2 Europe Prostate Cancer Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Prostate Cancer Market by Value
    • 4.3.2 Asia Pacific Prostate Cancer Market Forecast by Value
    • 4.3.3 China Prostate Cancer Market by Value
    • 4.3.4 China Prostate Cancer Market Forecast by Value
    • 4.3.5 China Prostate Cancer Market by Drug
    • 4.3.6 China Abiraterone Acetate Prostate Cancer Market by Value
    • 4.3.7 China Abiraterone Acetate Prostate Cancer Market Forecast by Value
    • 4.3.8 China Bicalutamide Prostate Cancer Market by Value
    • 4.3.9 China Bicalutamide Prostate Cancer Market Forecast by Value
    • 4.3.10 China Docetaxel Prostate Cancer Market by Value
    • 4.3.11 China Docetaxel Prostate Cancer Market Forecast by Value
  • 4.4 RoW
    • 4.4.1 RoW Prostate Cancer Market by Value
    • 4.4.2 RoW Prostate Cancer Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Increasing Geriatric Population
    • 5.1.2 Rising Healthcare Expenditure
    • 5.1.3 Surging Obese Population
    • 5.1.4 Rapid Urbanization
    • 5.1.5 New Drug Approvals
  • 5.2 Key Trends and Developments
    • 5.2.1 Growth of Pharmaceutical Industry
    • 5.2.2 Growing Burden of Prostate Cancer
    • 5.2.3 Advancements in Oncology
    • 5.2.4 Increasing Public Awareness
  • 5.3 Challenges
    • 5.3.1 Severe Side Effects of Treatment
    • 5.3.2 High Cost Associated with Treatment
    • 5.3.3 Prolonged Treatment Durations

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Revenue Comparison of Key Players
    • 6.1.2 Market Capitalization Comparison of Key Players
    • 6.1.3 R&D Comparison of Key Players
  • 6.2 Approved Drugs for Prostate Cancer
  • 6.3 Experimental Agents of Prostate Cancer

7. Company Profiles

  • 7.1 Johnson & Johnson
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Bayer AG
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Sanofi S.A.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 AbbVie Inc.
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 AstraZeneca PLC
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Astellas Pharma, Inc.
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.